Trading Statement

Hikma Pharmaceuticals Plc
23 January 2006



23 January 2006
                           Hikma Pharmaceuticals PLC

                                Trading statement

Hikma Pharmaceuticals PLC (LSE: HIK), the multinational pharmaceuticals group,
has continued to perform in line with market expectations, with each of the
Group's three businesses - Generic, Branded and Injectable Pharmaceuticals -
reporting increased sales compared to the same period in the financial year
ended 31 December 2004.

Hikma's Generic Pharmaceuticals business saw continued pricing pressure in 2005,
yet was able to achieve year-on-year sales growth through volume increases and
sales from 3 new product launches. Sales growth in the Branded Pharmaceuticals
business was driven by increasing sales across the Middle East and North Africa
(MENA) region. The Injectable Pharmaceuticals business experienced strong sales
growth in the US and the MENA region and benefited from increasing penetration
of European markets.

Hikma is pleased that it is continuing its track record of delivering robust
sales growth. Overall, the Group has achieved a strong financial performance for
the year, as anticipated when the Company listed on the London Stock Exchange on
1 November 2005. The Company continues to benefit from the strength and
diversity of its businesses and views the trading prospects of the Group for
2006 as positive.

Hikma will enter its close period on 30 January 2006 and will announce audited
preliminary results for the year ended 31 December 2005 on 29 March 2006.

                                    - ENDS -

Enquiries:

Hikma Pharmaceuticals plc

Bassam Kanaan, Chief Financial Officer                  [phone]
Susan Ringdal, Investor Relations Director              [phone]

Brunswick Group

Jon Coles / Wendel Verbeek / Justine McIlroy / 
Alex Tweed                                              [phone]


Notes to Editors

Hikma Pharmaceuticals plc (LSE: HIK) is a multinational pharmaceutical group
focused on developing, manufacturing and marketing a broad range of both branded
and non-branded generic and in-licensed pharmaceutical products. Hikma's
operations are conducted through three businesses: Generic, Branded and
Injectable Pharmaceuticals. Hikma's operations are based principally in the
United States, the Middle East and North Africa ('MENA') Region, and Europe. The
Company had net sales of $214m in 2004 and had approximately 1730 employees as
at 30 September 2005.



                      This information is provided by RNS
            The company news service from the London Stock Exchange